作者:Noronha, Dujon、Patil, Prashant B.、More, Kishor、Chandavarkar, Mohan Anand、Sawant, Sudhir
DOI:10.1021/acs.oprd.3c00449
日期:——
monograph. This improved process eliminated the need for column chromatography. There were only a few process impurities in the intermediates. The new approach described here is more efficient, with an overall yield of 37% with a quality of 99.8%, and sustainable than earlier processes reported in the literature, and it has the potential to become the commercial manufacturing route. This process was used
本研究详细介绍了一种新型改进工艺的开发,用于公斤级规模合成 β 受体阻滞剂药物盐酸倍他洛尔。环丙基甲基溴(CPMBr)与苯乙醇中间体缩合生成环氧乙烷中间体是合成中的重要步骤。然后与异丙胺反应生成倍他洛尔碱的外消旋体。通过山梨酸盐形成及其结晶对粗倍他洛尔碱进行纯化,使倍他洛尔碱达到所需的质量。它有助于根据国际协调会议 (ICH) 指南和欧洲药典 (EP) 专着中概述的规格要求实现所需的质量。这种改进的工艺消除了柱色谱法的需要。中间体中仅存在少量工艺杂质。这里描述的新方法比文献中报道的早期工艺更高效,总产率为 37%,质量为 99.8%,并且可持续,并且有潜力成为商业制造路线。该工艺以对羟基苯基乙醇为起始原料,无需柱层析纯化,即可生产 20 kg 规模的盐酸倍他洛尔,并提交监管机构的适用性证书 (CoS)。